Table 3.
Clinical characteristics in propensity-score matched cohort of 72 mUC patients.
| concurrent palliative radiation with pembro |
|||
|---|---|---|---|
| (-) | (+) | ||
| variables | n = 36 | n = 36 | p-value |
| age [mean + SD] (%) | 69.6 ± 9.0 | 70.1 ± 8.7 | 0.81 |
| ≦70 | 16(44.4) | 17(47.2) | |
| >70 | 20(55.6) | 19(52.8) | |
| sex (%) | |||
| male | 24(66.7) | 22(61.1) | |
| female | 12(33.3) | 14(38.9) | 0.62 |
| smoking history (%) | |||
| no | 10(27.8) | 16(44.4) | |
| yes | 26(72.2) | 20(55.6) | 0.14 |
| primary tumor (%) | |||
| bladder | 20(55.6) | 20(55.6) | |
| upper tract | 16(44.4) | 16(44.4) | 1.00 |
| histology (%) | |||
| pure UC | 32(88.9) | 32(88.9) | |
| others | 4(11.1) | 4(11.1) | 1.00 |
| denovo meta(%) | |||
| no | 21(58.3) | 20(55.6) | |
| yes | 15(41.7) | 16(44.4) | 0.81 |
| metastatic site at the initiation of pembrolizumab (%) | |||
| liver | 6(16.7) | 5(13.9) | 0.74 |
| lung | 10(27.8) | 17(47.2) | 0.08 |
| bone | 9(25) | 4(11.1) | 0.12 |
| regional lymph node | 16(44.4) | 11(30.6) | 0.22 |
| non regional lymph node | 16(44.4) | 18(50) | 0.64 |
| number of metastatic site at the initiation of pembrolizumab (%) | |||
| 1 | 20(55.6) | 19(52.8) | |
| 2≦ | 16(44.4) | 17(47.2) | 0.81 |
| ECOG-PS at the initiation of pembrolizumab (%) | |||
| 0 | 17(47.2) | 18(50) | |
| 1≦ | 19(52.8) | 18(50) | 0.81 |
| hemoglobin at the initiation of pembrolizumab [g/dl: mean ± SD] (%) | 10.8 ± 1.6 | 11.0 ± 1.5 | 1.00 |
| normal < | 6(16.7) | 6(16.7) | |
| normal ≧ | 30(83.3) | 30(83.3) | |
| NLR at the initiation of pembrolizumab [mean ± SD] (%) | 3.8 ± 3.3 | 4.2 ± 5.0 | 1.00 |
| 3.7< | 10(27.8) | 10(27.8) | |
| 3.7≧ | 26(72.2) | 26(72.2) | |
mUC: metastatic urothelial carcinoma, SD: standard deviation, ECOG-PS: Eastern Cooperative Oncology Group Performance Status, NLR: neutrophil–lymphocyte ratio.